Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

NVS 88.41 -0.72 (-0.81%)
price chart
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
Novartis' second quarter results were disappointing. Core earnings per share came in at $1.34, up 7% from the year-ago period but missed the Zacks Consensus Estimate of $1.36.
Related articles »  
Novartis To Offer Stiff Competition To Amgen's Neupogen
Novartis AG (ADR) (NVS) announced yesterday that the Food and Drug Administration (FDA) had accepted the Biologics License Application for filgrastim by Sandoz - the generics arm of Novartis.
Related articles »  
Novartis AG (ADR) (NVS) Beats Analyst Estimates; Is Expected To Perform Well ...
On the deal between Novartis AG (ADR) (NYSE:NVS) and Google Inc. (NASDAQ:GOOGL), Rundquist said that the deal is interesting for both the companies and the deal represents a new way to thinking in healthcare, by combining bio-technology healthcare ...
Related articles »  
Google Inc (GOOGL) and Novartis AG (ADR) (NVS) Join Hands to Develop ...
Tech giants are now focusing excessively on wearables that can help users to track health-related issues. According to a report by Bloomberg, Google Inc (NASDAQ:GOOGL) and Novartis AG (ADR) (NYSE:NVS) now have a deal according to which both ...
Google Inc (NASDAQ GOOG) partners with Novartis to develop New Contact Lens  Tech News
Related articles »  
Biotech Stocks With Unique Diagnostic and Therapeutic Technologies [Novartis ...
For example, Genentech/Roche Holding AG's (RHHBY:OTCQX) Herceptin is almost a $7 billion ($7B) global franchise, but only 20-30% of all breast cancer patients are positive for HER2 (human epidermal growth factor receptor 2), and will respond to the ...
Related articles »  
Novartis AG (ADR) (NYSE:NVS), Profit Misses Estimates; Forecast Confirmed
Novartis AG's pharmaceuticals division provides patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and ...
Novartis Sees Lower-Than-Expected Profits  Bidness Etc
Novartis AG Misses Earnings Estimates  ValueWalk
Related articles »  
Foreign Companies News: Rio Tinto plc (ADR) (RIO), Novartis AG (ADR) (NVS ...
Novartis AG (ADR) (NYSE:NVS) posted second-quarter results today, and profits missed analyst estimates. The world's largest drugmaker by sales reported a 2% increase in sales, to $14.6 billion, missing analysts' projections of $14.8 billion, and a 3% ...
Novartis AG (ADR) (NYSE:NVS) Posted Second-Quarter Profit, Hauled By ...  eFinance Hub
Just In: BP plc (ADR) (NYSE:BP), Novartis AG (ADR)(NYSE:NVS)  Market News Call
Related articles »  
Novartis And Google Join Hands To Develop 'Smart' Lens
Novartis AG (NVS) announced today that it has signed a deal with tech giant Google Inc. (GOOG) to develop smart lens technology, for medical purposes specifically pertaining to the eye.
Google Inc (GOOG), Novartis AG To Develop Smart Glucose-Tracking Contact ...  Opptrends
Google, Novartis Partner To Revolutionize Healthcare  ValueWalk
Related articles »  
Novartis Determined To Counter Alzheimer's Disease
Novartis AG (ADR) (NVS) says it is will partner with the Banner Alzheimer's Institute to conduct a study on preventing Alzheimer's.
Related articles »  
Watch List - Incyte Corporation (INCY), Novartis AG (ADR) (NVS), ACADIA ...
Novartis AG (ADR) (NYSE:NVS) deals in patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical ...